logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics announces publication of positive data of Pollinex Quattro Grass vaccines

The company said each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy

allergy
“We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally," CEO Manuel Llobet said

Allergy Therapeutics plc (LON:AGY) has announced the publication of positive data in the journal Immunotherapy, demonstrating the long-lasting efficacy of Pollinex Quattro grass in patients with grass pollen allergy.

The AIM-listed firm said the observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. 

READ: Allergy Therapeutics announces positive new clinic data with house-dust mite immunotherapy

The company, specialising in allergy vaccines, said each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy.

Allergy Therapeutics said the study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment.

Manuel Llobet, CEO at Allergy Therapeutics, said: ”Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates.”

He added: “We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market."

Quick facts: Allergy Therapeutics PLC

Price: 11 GBX

AIM:AGY
Market: AIM
Market Cap: £69.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read